Hi-Clearance Inc. (TPEX:1788)
Taiwan
· Delayed Price · Currency is TWD 144.50
-0.50 (-0.34%)
Feb 21, 2025, 1:30 PM CST
Hi-Clearance Revenue
Hi-Clearance had revenue of 1.01B TWD in the quarter ending September 30, 2024, with 2.50% growth. This brings the company's revenue in the last twelve months to 4.05B, up 4.67% year-over-year. In the year 2023, Hi-Clearance had annual revenue of 3.90B, down -16.93%.
Revenue (ttm)
4.05B
Revenue Growth
+4.67%
P/S Ratio
1.59
Revenue / Employee
n/a
Employees
n/a
Market Cap
6.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.90B | -793.91M | -16.93% |
| Dec 31, 2022 | 4.69B | 1.01B | 27.30% |
| Dec 31, 2021 | 3.68B | 252.04M | 7.34% |
| Dec 31, 2020 | 3.43B | 191.25M | 5.90% |
| Dec 31, 2019 | 3.24B | 145.57M | 4.70% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 8.32B |
| Caliway Biopharmaceuticals | 44.43M |
| Bora Pharmaceuticals Co., LTD. | 16.71B |
| Lotus Pharmaceutical | 17.59B |
| Lumosa Therapeutics | 37.82M |
| Oneness Biotech | 112.20M |
| Polaris Group | 75.65M |
| Pegavision | 7.06B |